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Abstract
Background: Tumor-associated macrophages (TAMs) are alternatively activated cells induced by interleukin-4 (IL-4)-
releasing CD4
+ T cells. TAMs promote breast cancer invasion and metastasis; however, the mechanisms underlying
these interactions between macrophages and tumor cells that lead to cancer metastasis remain elusive. Previous
studies have found microRNAs (miRNAs) circulating in the peripheral blood and have identified microvesicles, or
exosomes, as mediators of cell-cell communication. Therefore, one alternative mechanism for the promotion of
breast cancer cell invasion by TAMs may be through macrophage-secreted exosomes, which would deliver
invasion-potentiating miRNAs to breast cancer cells.
Results: We utilized a co-culture system with IL-4-activated macrophages and breast cancer cells to verify that
miRNAs are transported from macrophages to breast cancer cells. The shuttling of fluorescently-labeled exogenous
miRNAs from IL-4-activated macrophages to co-cultivated breast cancer cells without direct cell-cell contact was
observed. miR-223, a miRNA specific for IL-4-activated macrophages, was detected within the exosomes released
by macrophages and was significantly elevated in the co-cultivated SKBR3 and MDA-MB-231 cells. The invasiveness
of the co-cultivated breast cancer cells decreased when the IL-4-activated macrophages were treated with a miR-
223 antisense oligonucleotide (ASO) that would inhibit miR-223 expression. Furthermore, results from a functional
assay revealed that miR-223 promoted the invasion of breast cancer cells via the Mef2c-b-catenin pathway.
Conclusions: We conclude that macrophages regulate the invasiveness of breast cancer cells through exosome-
mediated delivery of oncogenic miRNAs. Our data provide insight into the mechanisms underlying the metastasis-
promoting interactions between macrophages and breast cancer cells.
Background
Breast cancer is the most common malignant tumor in
women, and distal metastasis of highly invasive breast
cancer cells is the major cause of death in these women.
Tumor-associated macrophages that infiltrate the breast
cancer stroma are the most notable migratory hemato-
poietic cell-type in the tumor microenvironment and
function to promote the invasiveness of breast cancer
cells [1-4]. Macrophages are heterogeneous cells that
respond differently to various stimulating signals and
display numerous phenotypes [5]. Fully polarized M1, or
classically activated, macrophages are stimulated by
microbial agents or pro-inflammatory factors, such as
lipopolysaccharides (LPS); whereas M2, or alternatively-
activated, macrophages are responding to anti-inflam-
matory molecules, such as interleukin-4 (IL-4). The M1
and M2 macrophage phenotypes represent the two
extremes of a broad range of macrophage functional
states. Among these functional states, M2 macrophages
activated by IL-4 have been associated with breast can-
cer invasion, metastasis and poor patient prognosis
[2,6-10].
Previous studies have shown that TAMs promote
breast cancer progression and metastasis by releasing a
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siveness of tumor cells and stimulate tumor angiogen-
esis [11,12]. More recent data have demonstrated that
macrophages are able to produce microvesicles, also
known as exosomes, which shuttle proteins or micro-
RNAs (miRNAs) into adjacent cells within the microen-
vironment [13,14]. Exosomes are derived from
multivesicular endosomes that fuse with the plasma
membrane and are shed into the extracellular space.
These particles range in size from 50 to 100 nm. A wide
variety of cells may release exosomes, but their contents
vary depending on the cell-type of origin and its activa-
tion status [15]. One topic of considerable interest is
that exosomes contain miRNAs that mediate intercellu-
lar communication [16-19]. miRNAs are short, non-cod-
ing RNAs that regulate the expression of
complementary mRNAs [20]. The shuttling of these
molecules between cells aids in regulating the biology of
target cells. miR-223 is specific for alternatively-activated
M2 macrophages induced by IL-4 and is associated with
the regulation of human granulopoiesis [21].
In the present study, we demonstrate that exogenous
miRNAs transfected into IL-4-activated M2 macro-
phages can be shuttled into co-cultivated breast cancer
cells in the absence of direct cell-cell contact with the
macrophages. Exosomes containing miR-223 were
released by M2 cells and were then internalized by co-
cultivated breast cancer cells that did not express this
miRNA. The exosome-shuttled miR-223 promoted the
invasiveness of breast cancer cells in vitro. This process
of invasion could be inhibited by transfecting miR-223
antisense oligonucleotides (ASO) into the tumor cells.
Our study provides evidence for the delivery of inva-
sion-potentiating miR-223 by IL-4-activated macro-
phages to breast cancer cells via exosomes and may
highlight a novel communication mechanism between
TAMs and cancer cells.
Methods
Isolation and activation of human monocyte-derived
macrophages
Institutional approval from the local research ethical
committees (Internal Review and the Ethics Boards of
the Sun-Yat-Sen Memorial Hospital, Sun-Yat-Sen Uni-
versity) was obtained prior to conducting the study.
Human mononuclear cells were isolated from the per-
ipheral blood of healthy donors by Ficoll density gradi-
ent centrifugation at 450 × g for 25 min at room
temperature. The mononuclear cells were washed three
times with PBS and plated at a density of 5 × 10
6 per
well in 24-well plates and incubated for 1.5 h in DMEM
alone. Subsequently, non-adherent cells were washed
away with warm Hank’s solution, and the adherent
monocytes were cultured in DMEM containing 10%
fetal bovine serum (FBS). Media was changed every 3
days, and the resulting monocyte-derived macrophages
(MDMs) were activated by adding IL-4 (45 ng/ml) to
the culture medium for 3 days.
Cell cultures and co-cultivation
HEK-293T cells and the breast cancer cell lines, SKBR3
and MDA-MB-231, were cultured in DMEM containing
10% FBS. Co-cultivation of macrophages and breast can-
cer cells was performed in 24-well Boyden chambers
(Corning, cat. no. 3413). Macrophages were seeded on
the 0.4 μM inserts, which are permeable to supernatants
but not to cellular components. Breast cancer cells were
seeded in the lower chambers and grown for the indi-
cated periods of time.
Microarray
MicroRNA expression profiles were generated as
described previously [22], and hybridization using Disco-
vArray miRNA arrays was performed according to the
manufacturer’s instructions.
Quantitative reverse transcription-PCR
Quantitative real-time reverse transcription-PCR (qRT-
PCR) for miR-223 was conducted using Real-Time PCR
Universal Reagent (GenePharma Co., Ltd.) and the MX-
3000P Real-Time PCR machine (Stratagene). All reac-
tions were performed in a 20 μL reaction volume in tri-
plicate. The primers used for miR-223 and U6 snRNA
are as follows: miR-223 forward, 5’CATTGTCAGTT
TGTCAAATACC3’; miR-223 reverse, 5’CCATGAGA-
GATCCCTAGCG3’ and U6 snRNA forward, 5’ATTG-
GAACGATACAGAGAAGAT3’; U6 snRNA reverse,
5’GGAACGCTTCACGAATTT3’. PCR amplification
consisted of an initial denaturation step at 95°C for 3
min, followed by 40 cycles of 95°C for 30 s, 62°C for 40
s, and 72°C for 30 s. Standard curves were generated,
and the relative amount of miR-223 was normalized to
the amount of U6 snRNA (2
- ΔCt).
Luciferase reporter plasmid construction
The pMIR-REPORT miRNA expression reporter (firefly
luciferase reporter plasmid; Ambion) was used for plas-
mid construction. The 3’-UTR of Mef2c,c o n t a i n i n gt w o
miR-223 target sequences, miR-223 complementary
sequence (TGGGGTATTTGACAAACTGACA) and lin-
4 complementary sequence (CTAGTCACACTT-
GAGGTCTCAGGGA), were separately cloned into the
3’-UTR of the pMIR-REPORT plasmid according to the
manufacturer’s instructions (Ambion).
Invasion assay
Invasion was measured by assessing the cell migration
rate through an artificial basement membrane in a
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membrane consisted of polycarbonate (8 μmp o r ed i a -
meter) and was coated on ice with Matrigel (BD Bios-
ciences) diluted in serum-free DMEM. Cells
resuspended in DMEM were seeded into the upper well
of the chamber (100 μl), while the lower well was filled
to the top (approximately 600 μl) with complete med-
ium (DMEM containing 10% FBS). Cells were incubated
for 4-8 h. The cells in the upper well that did not
migrate were scraped off, and the cells that migrated
onto the outer side of the upper well membrane were
stained with crystal violet. Invading cells were observed
under a microscope and counted for statistical analysis.
Transfection of miRNA mimics and miRNA ASO
MicroRNA mimics and inhibitors (miRNA antisense oli-
gonucleotides (ASO)) were purchased from GenePharma
Co., Ltd. The sequences are provided in Table 1. In
vitro transfection of miRNAs (miR-223, lin-4 and miR-
NC) and miRNA ASO (miR-223 ASO and miR-NC
ASO) were performed using X-tremeGENE siRNA
Transfection Reagent according to the manufacturer’s
instructions (Roche, cat. no. 04 476 093 001).
Luciferase assays
To determine whether miRNAs were shuttled from
macrophages to breast cancer cells, the levels of miR-
NAs in the target cancer cells were assessed using luci-
ferase assays. Briefly, the pMIR-REPORT vector with
either the miR-223 or the lin-4 complementary
sequence in its 3’-UTR (firefly luciferase reporter vector,
Ambion) were transfected into SKBR3 cells using Lipo-
fectamine2000 (Invitrogen) according to the manufac-
turer’s instructions. A Renilla luciferase vector
(Promega) was co-transfected as an internal control for
normalization. After transfection, cells were washed to
remove untransfected plasmids or miRNAs. SKBR3 cells
were then co-cultivated in Boyden chambers with
macrophages activated with IL-4 or transfected with lin-
4 mimics, as described above, for 24-72 h. pMIR-
REPORT and Renilla luciferase activities were assayed
using the Dual-Luciferase assay kit (Promega). pMIR-
REPORT luciferase activity was normalized to the
Renilla luciferase activity. To determine whether Mef2c
mRNA is a target of miR-223, the pMIR-REPORT vec-
tor containing the 3’-UTR of Mef2c was co-transfected
with miR-223 into HEK-293T cells. After 24-48 h of
incubation, the cells were lysed, and luciferase activity
was detected as described above.
Shuttling assays for fluorescently-labeled miRNA
To further visualize the shuttling of miRNAs, Cy3-
labeled miRNAs (GenePharma) were transfected into
macrophages, as described above. Macrophages were
washed to remove the residual transfection reagent 24-h
after transfection. Macrophages carrying Cy3-miRNA
were then placed onto transwell inserts, and SKBR3
cells were seeded in the lower wells of Boyden cham-
bers. After incubation for 24-48 h, SKBR3 cells were
collected for fluorescence microscopy and flow cyto-
metric analyses.
Western blots
Cells were lysed with RIPA lysis buffer and protease inhi-
bitors (Sigma-Aldrich). Nuclear protein was collected
according to previously described protocols [23]. A total
of 20 μg of protein per sample was separated on SDS-
PAGE gels and transferred onto nitrocellulose membranes.
Membranes were blocked and incubated with antibodies
against b-catenin (1:1000, Cell Signaling Technology,
#9587) or Mef2c (1:1000, Cell Signaling Technology,
#9792) overnight at 4°C. Primary antibody incubation was
followed by incubation with HRP-conjugated secondary
antibodies (Amersham Pharmacia). HRP signals were then
visualized by enhanced chemiluminescence (Pierce).
Confocal microscopy
Cells prepared on coverslips were fixed in 4% PFA, trea-
ted with 0.3% Triton X-100, blocked with 5% BSA and
incubated with an anti-b-catenin antibody (1:200, Cell
Signaling Technology, #9587) overnight at 4°C. After
being washed with PBS, cells were incubated with a
FITC-conjugated secondary antibody for 1 h and coun-
terstained with PI prior to inspection under a confocal
microscope.
Immunofluorescence
SKBR3 breast cancer cells were co-cultured with Cy3-
preloaded macrophages for 24-48 h. After co-culture,
both macrophages and SKBR3 were fixed in 4% PFA,
treated with 0.1% Triton X-100, blocked in 3% BSA and
incubated with an anti-CD68 antibody (1:200, Dako) for
2 h at room temperature. After being washed, cells were
incubated with an Alexa Fluor 488-conjugated second-
ary antibody, and then counterstained with DAPI before
inspection under fluorescence microscope.
Immunohistochemistry
All tumor samples of invasive breast cancer were
obtained from female patients at the No. 2 Affiliated
Table 1 The sequences of microRNA mimics and
inhibitors
hsa-miR-223 UGUCAGUUUGUCAAAUACCCCA
miR-NC (negative control) UUCUCCGAACGUGUCACGUTT
hsa-miR-223 inhibitor (ASO) UGGGGUAUUUGACAAACUGACA
miR-NC ASO CAGUACUUUUGUGUAGUACAA
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were collected with informed consent according to the
Internal Review and the Ethics Boards of the Sun-Yat-
Sen Memorial Hospital, Sun-Yat-Sen University. Sam-
ples were fixed, paraffin embedded and sectioned into
5- μM slices. Macrophages were visualized by immuno-
histochemistry staining using an anti-CD68 (1:200,
Dako) antibody. Bound primary antibody was detected
by using a horseradish peroxidase conjugated secondary
antibody, which was then developed in DAB solution
(Dako). Pictures were taken under a light microscope.
Exosome purification and labeling
The same number of IL-4-activated or unactivated
macrophages were cultured in exosome-free medium
(DMEM containing 10% FBS that was depleted of exo-
somes by ultra-centrifuging at 100,000 × g for 18 h).
Conditioned media were collected after 3-5 days of
incubation. Exosomes were purified by differential cen-
trifugation. Briefly, the conditioned media were centri-
f u g e da t5 0 0×g for 30 min and 16,500 × g for 20 min
to eliminate cells and cellular debris, respectively. Super-
natants were filtered through 0.22 μm filters. Exosomes
were pelleted by ultracentrifugation at 120,000 × g for
180 min, washed in PBS, pelleted again and resuspended
in PBS. Exosome preparations were stained with CM-
DiI (CellTracker, C7000), a fluorescent dye that labels
the plasma membrane, according to the manufacturer’s
instructions. Next, exosomes were diluted in complete
medium (DMEM with 10% FBS) and were added into
the cell cultures. At the indicated time points, cells were
examined under a confocal microscope and analyzed
using flow cytometry.
RNase treatment of Exosomes
The culture of unactivated and IL-4-activated macro-
phages and the process through which exosomes were
collected are described above. Exosomes were treated
with RNase according to previously described protocols
[24]. Briefly, separated exosomes were incubated with
RNase A at a final concentration of 100 U/ml, with or
without 1% Triton X-100, at room temperature for 30
min. Exosomes were washed with PBS to remove resi-
dual RNase and Triton X-100. Exosomes were incubated
with breast cancer cells prior to performing invasion
assays.
Electronic microscopy
Exosome preparations were mixed with equal quantities
of freshly prepared 4% paraformaldehyde for 20 min.
Samples were washed in water, pelleted by ultracentrifu-
gation and then fixed for 5 min in 1% glutaraldehyde.
After this process, exosomes were re-suspended in
water, and 5 μl of the samples were loaded onto carbon-
coated formvar grids. Exosomes were stained for 10 min
with saturated aqueous uranyl and examined using an
electron microscope (Hitachi S-4800 FEG SEM).
Statistical analyses
All data are expressed as mean ± SD. Statistical analyses
were performed using paired Student’s t-tests.
Results
Co-cultivation with IL-4-activated macrophages elevates
miR-223 levels in breast cancer cells
Because TAMs located in the stroma of breast cancers
are primarily M2 macrophages activated by IL-4-pro-
ducing CD4
+ T cells [25], we mimicked this TAM-
populated microenvironment by co-cultivating SKBR3
breast cancer cells with IL-4-activated MDMs in a
Boyden chamber, which prevents direct cell-cell con-
tact. To optimize a physiologically-relevant cell num-
ber ratio for the co-culture experiments, we quantified
the amount of macrophage infiltration present in
patient samples that were pathologically diagnosed as
invasive breast cancer. As shown in Additional file 1
Figure S1(A), a large number of macrophages (CD68-
positive) infiltrated breast tumors, especially in the
tumor-associated stromal border, where many invasive
tumor cells were also located. Because previous studies
suggested that macrophages produce exosomes, which
shuttle proteins or microRNAs (miRNAs) into adjacent
cells within the microenvironment, we focused on the
neighboring tumor cells and macrophages. We calcu-
lated the cell ratio based upon the neighboring tumor
cell and macrophage populations in a local context as
indicated in Additional file 1 Figure S1(B). The ratio of
tumor cells to their adjacent macrophages ranged from
1:1 to 1:7. Subsequently, we tested the effects of
macrophage to breast cancer cell ratios, ranging from
1:1 to 5:1, in the co-culture system. The effects of
macrophages on breast cancer cells were observed at
ratios starting from 1:1. First, we screened for miRNAs
that were differentially expressed between macrophages
and breast cancer cells using a DiscovArray miRNA
microarray. All the microarray data were listed in
Additional file 2 Table S1. We found three microRNAs
that were abundantly expressed in macrophages but
not in SKBR3 or MDA-MB-231 breast cancer cells
(Figure 1A). Using qRT-PCR, we confirmed that miR-
223 was overexpressed in IL-4-activated MDMs but
was not highly expressed in either SKBR3 or MDA-
MB-231 breast cancer cells (Figure 1B). Additionally,
miR-223 is involved in cancer progression [26,27];
therefore, we focused on miR-223 expression levels in
breast cancer cells after co-cultivation with IL-4-acti-
vated MDMs. We seeded breast cancer cells and
macrophages in co-culture Boyden chambers, as
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cells co-cultured with IL-4-activated macrophages
exhibited a profound increase in cellular miR-223
levels (2.7 ± 0.5- and 3.3 ± 0.98-fold in SKBR3 and
MDA-MB-231 cells, respectively) relative to cells that
were not co-cultured (blank) or were co-cultured with
unactivated macrophages (Figure 1C). To evaluate the
function of elevated miR-223 in breast cancer cells, we
used a luciferase reporter gene containing a sequence
complementary to miR-223 in its 3’-UTR. Co-culturing
with IL-4-activated macrophages reduced luciferase
reporter activity in SKBR3 breast cancer cells (Figure
1D and Additional file 3 Figure S2), which suggests
that the elevated miR-223 levels observed in breast
cancer cells are capable of silencing target gene expres-
sion. Furthermore, direct transfection of miR-223
mimics, but not a scrambled negative control miRNA
(miR-NC), also suppressed the reporter gene activity in
SKBR3 cells (Figure 1D). These data suggest that co-
culturing breast cancer cells with IL-4-activated
macrophages increases the level of functional miR-223
in breast cancer cells.
miRNAs released by macrophages are shuttled into
breast cancer cells
To determine whether miRNAs released by IL-4-acti-
vated macrophages are shuttled into co-cultured breast
cancer cells, we transfected macrophages with either
Cy3-labeled miR-223 or non-mammalian lin-4 miRNA
prior to co-culture with SKBR3 cells. Co-culture was
performed in a 24-well Boyden chamber with a 0.4- μm
insert (Figure 2A). Fluorescence microscopy analysis
indicated the presence of Cy3-miRNA in SKBR3 cells,
with approximately 15 positive cells per field of view,
when co-cultured with macrophages transfected with
Cy3-labeled miR-223. Fluorescence was not detected in
cells that were not co-cultured or that were co-cultured
with macrophages transfected with unlabeled miR-223
Figure 1 miR-223 was up-regulated in breast cancer cell lines co-cultured with IL-4-activated macrophages.( A )m i R N Ap r o f i l i n gi n
macrophages and the breast cancer cell line SKBR3 using the DiscovArray miRNA array. Three of the miRNAs that were present at high levels in
macrophages but absent in SKBR3 cells are shown. (Un-Mac, unactivated macrophages; IL4-Mac, IL-4-activated macrophages). (B) Quantitative
real-time PCR (qRT-PCR) confirmed a high expression level of hsa-miR-223 in macrophages but not in SKBR3 or MDA-MB-231 cells. * p < 0.05. (C)
Co-culture of breast cancer cells with macrophages increased miR-223 levels in breast cancer cells. Breast cancer cell lines (SKBR3 and MDA-MB-
231) were cultured alone (blank) or co-cultured with unactivated or IL-4-activated macrophages without direct cell-cell contact. miR-223
expression in SKBR3 and MDA-MB-231 cells was detected using qRT-PCR. Relative levels of miR-223 expression normalised to U6 rRNA levels are
presented. * p < 0.05. (D) Functional assay of miR-223 in breast cancer cells. miR-223-targeting luciferase reporter containing a miR-223
complementary sequence within the 3’-UTR of the luciferase reporter gene was constructed. SKBR3 cells were transfected with the reporter gene
and cultured alone (blank) or co-cultured with IL-4-activated macrophages. As controls, SKBR3 cells were co-transfected with the reporter gene
and miR-NC, miR-660 or miR-223. Relative luciferase activities (normalised to Renilla luciferase activity) are presented. * p < 0.05.
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Page 5 of 13Figure 2 Functional microRNA is shuttled from macrophages to breast cancer cells. (A) Schematic illustration of a miRNA transfer model.
Macrophages were preloaded with Cy3 fluorescently-labeled miR-223 or the non-mammalian miRNA lin-4. A transwell system with a 0.4- μm
pore size film, which allows small size materials (e.g., miRNAs), but not cells, to pass through, was used to separate SKBR3 cells from
macrophages. (B) and (C) SKBR3 cells were cultured alone (blank) or co-cultured with macrophages that were pre-transfected with reagent
(mock), unlabeled miR-223 or Cy3-miR-223. The Cy3 fluorescence signal in SKBR3 cells was determined by fluorescence microscopy (B), and the
percentage of Cy3-positive cells in the images was calculated in (C). Arrowheads indicate Cy3-positive SKBR3 cells, and images are shown at
200×. (D) SKBR3 cells were cultured as shown in (B), and Cy3-positive cells (%) were quantified by flow cytometry. (E) A lin-4-targeting luciferase
reporter gene carrying a lin-4 complementary sequence in the 3’-UTR was transfected into SKBR3 cells. SKBR3 cells were then co-cultured in a
transwell with macrophages pre-transfected with miR-NC or lin-4. SKBR3 cells that were directly transfected with lin-4 were used as a control.
Luciferase activities in SKBR3 cells were measured, and relative luciferase activities (normalised to Renilla luciferase activity) are presented.*p<
0.05. (Un-Mac, unactivated macrophages; IL4-Mac, IL-4-activated macrophages).
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penetrate through the 0.4- μm pore size membrane.
However, to verify that the co-cultivated fluorescent
tumor cells were not contaminated with macrophages,
we stained these cells for CD68, a macrophage marker.
As shown in Additional file 4 Figure S3, after being co-
cultured with Cy3-preloaded macrophages, no CD68
staining was detected among the Cy3-positive cells.
Furthermore, flow cytometric analysis confirmed that
13.8% of SKBR3 cells co-cultured with IL-4-activated
macrophages that were preloaded with Cy3-labeled
miR-223 were positive for Cy3-miRNA (Figure 2D).
T h e s ed a t as u g g e s tt h a tm i R N A sw i t h i nm a c r o p h a g e s
can be physically transported into adjacent cancer cells.
To determine whether the miRNAs shuttled from
macrophages retained their gene-silencing function in
the recipient cells, we used a non-mammalian miRNA,
lin-4, and its target reporter gene (luciferase reporter
containing a lin-4 complementary sequence in its 3’-
UTR). Prior to co-cultivation, IL-4-activated macro-
phages were transfected with either control (NC) or lin-
4 miRNA, and SKBR3 breast cancer cells were trans-
fected with a luciferase reporter gene with a lin-4 target
sequence at its 3’-UTR. Luciferase activity was sup-
pressed in SKBR3 cells co-cultured with macrophages
transfected with lin-4, while this suppression was not
observed in cells co-cultured with the control NC
miRNA macrophages. Transfection of SKBR3 cells with
lin-4 was used as a control to demonstrate a significant
reduction in luciferase activity of the lin-4 reporter gene
(Figure 2E).
Exosomes released from IL-4-activated macrophages
mediate miRNA shuttling
Previous studies have demonstrated that microvesicles,
or exosomes, secreted from macrophages may serve as
vesicles that mediate cell-to-cell exchange of small
RNAs. To further confirm that exosomes released from
macrophages mediate miR-223 transfer, exosomes
released from macrophages were purified by gradient
centrifugation. Consistent with previous findings, elec-
tron microscopy revealed that exosomes released from
the unactivated and IL-4-activated macrophages were
nanometer-sized particles with bilayer membranes (Fig-
ure 3A) [16]. The exosomes derived from unactivated
macrophages were much larger in size, with a diameter
of 222 ± 52 nm, while those derived from IL-4-activated
macrophages were smaller, with a diameter of 57 ± 21
nm (Figure 3B). Additionally, qRT-PCR data demon-
strated the presence of miR-223 in the exosomes of
both subtypes of macrophages, while those released
from IL-4-activated macrophages contained higher levels
of miR-223 than those from the unactivated cells (p <
0.01) (Figure 3C). To visualize exosome uptake in breast
cancer cells, SKBR3 cells were incubated with CM-DiI-
l a b e l e de x o s o m e st h a tw e r ei s o l a t e df r o mm a c r o p h a g e s .
Internalization of CM-DiI-labeled exosomes was
detected in SKBR3 cells by confocal microscopy (Figure
3E). The number of cells with internalized exosomes
increased in a time-dependent manner and reached a
plateau at 24 h (Figure 3D). Interestingly, exosomes
released from IL-4-activated macrophages were interna-
lized more efficiently than those released from unacti-
vated macrophages (Figure 3D). In parallel, Cy3-labeled
miR-223 from IL-4-activated macrophages was more
efficiently transported into SKBR3 breast cancer cells
(13.36 ± 3.52%) than the labeled miR-223 from unacti-
vated macrophages (7.85 ± 2.84%) (Additional file 5 Fig-
ure S4). Taken together, these data suggest that
macrophage-secreted exosomes mediate miR-223
shuttling.
miR-223 promotes breast cancer cell invasion
miR-223 has been implicated in the progression of renal
[26] and hepatocellular cancers [27]. Consistent with
previous studies, co-culture with IL-4-activated macro-
phages enhanced breast cancer cell invasion relative to
control cells cultured alone or to co-culture with unacti-
vated macrophages (Figure 4A). To determine the biolo-
gical function of miR-223 uptake by breast cancer cells,
we first examined the effects of miR-223 on breast can-
cer cell invasion by directly transfecting miR-223 mimics
into SKBR3 or MDA-MB-231 cells. Cell invasiveness
was determined using a transwell invasion assay. Indeed,
significantly more miR-223-transfected breast cancer
cells invaded across the Matrigel-coated inserts as com-
pared to miR-NC-transfected cells (Figure 4B). We also
tested the invasion-promoting potential of exosomes
from both unactivated and IL-4-activated macrophages.
SKBR3 cells were incubated with exosomes purified
from equal numbers of IL-4-activated and unactivated
macrophages. Exosomes isolated from IL-4-activated
macrophages promoted SKBR3 invasion, whereas the
same effect was not observed with those isolated from
unactivated macrophages (Figure 4C). Additionally, the
invasion-promoting activity by exosomes derived from
IL-4-activated macrophages was alleviated by miR-223-
ASO (Figure 4C). Next, we treated exosomes derived
from macrophages with RNase plus triton X-100 and
incubated those exosomes with SKBR3 cells. Exosomes
derived from IL-4-activiated macrophages treated with
RNase plus triton X-100 had decreased invasion poten-
tial compared to the blank and RNase alone groups. In
contrast, no significant differences were observed in the
invasion potential of RNase plus triton X-100 treated
exosomes derived from unactivated macrophages (Addi-
tional file 6 Figure S5). Moreover, the invasiveness of
the co-cultivated breast cancer cells decreased when we
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(Additional file 7 Figure S6). Similarly, breast cancer
cells preloaded with miR-223-ASO had decreased inva-
siveness when co-cultured with IL-4-activated macro-
phages (Additional file 8 Figure S7). These data suggest
that miR-223 uptake by breast cancer cells is associated
with the promotion of invasiveness.
miR-223 targets the Mef2c-b-catenin pathway
Previous studies have suggested that miR-223 targets the
myocyte enhancer factor, Mef2c, in myeloid progenitor cells
to inhibit their proliferation and granulocyte function [28].
Using TargetScan, we identified two miR-223 target sites in
the Mef2c 3’-UTR. To understand the mechanism by which
miR-223 promotes breast cancer cell invasion, we assessed
whether miR-223 targets Mef2c in breast cancer cells. HEK-
293T cells were transfected with a luciferase reporter vec-
tor, pMIR-REPORTER-Mef2c, that contained the cloned
Mef2c 3’-UTR. After approximately 24-48 h, cells were
lysed and luciferase activity was determined, as described
above. As depicted in Figure 5A, transfection with miR-223
inhibited the luciferase activity of the Mef2c reporter gene
but did not reduce the activity of the control luciferase vec-
t o rt h a td i dn o th a v et h eMef2c 3’-UTR. This inhibition was
Figure 3 Exosomes secreted from macrophages shuttle miR-223 to breast cancer cells. (A) Exosomes secreted from unactivated and IL-4-
activated macrophages were collected and observed with an electron microscope. Exosomes derived from unactivated macrophages (un-Mac-
origin) were larger in size (100-250 nm) than those derived from IL-4-activated macrophages (IL-4-Mac-origin) (50-80 nm). Scale bars are as
indicated. (B) The diameter of exosomes derived from unactivated and IL-4-activated macrophages were quantified. Data are averages of more
than 10 exosomes from each group. (C) Levels of miR-223 expression in exosomes were quantified by qRT-PCR. ** p < 0.01. (D) and (E)
Exosomes derived from IL-4-activated macrophages were more readily internalised by breast cancer cells. Exosomes derived from unactivated
and IL-4-activated macrophages were labeled with CM-Dil and incubated with SKBR3 cells for the indicated times (0-40 h). Uptake of exosomes
by cancer cells was visualized by confocal microscopy (representative images are shown in (E) and quantified by flow cytometry in (D)). (Un-Mac,
unactivated macrophages; IL4-Mac, IL-4-activated macrophages).
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Page 8 of 13not observed in the miR-NC-transfected cells. Moreover,
western blot analysis demonstrated that transfection with
miR-223 reduced the levels of endogenous Mef2c in SKBR3
cells (Figure 5B). As Mef2c reduction has been linked to
nuclear accumulation of b-catenin and the promotion of
cell migration [29,30], we further examined whether miR-
223 regulates nuclear translocation of b-catenin. Western
blotting of cellular fractions demonstrated that transfection
with miR-223 dramatically increased b-catenin expression
in the nuclei of breast cancer cells (Figure 5B). Additionally,
indirect fluorescence microscopy revealed localization of b-
catenin in the nuclei of breast cancer cells transfected with
miR-223 (Figure 5C). Based on these results, we conclude
that miR-223 may target the Mef2c-b-catenin pathway to
mediate breast cancer cell invasion.
Discussion
Interactions between macrophages and breast cancer
cells result in more invasive cancer cells, metastasis and
poor patient prognosis. Preventing malignant breast
epithelium-macrophage communication may inhibit the
metastatic cascade during cancer progression [2,9], and
thereby, provide important treatment targets for breast
cancer therapy. Consequently, the mechanisms underly-
ing breast cancer cell-macrophage interactions require
further investigation. Most current studies focus on the
cytokines, molecules or enzymes that are secreted by
macrophages; however, greater attention is needed on
miRNAs due to their regulatory effects on cancer cell
progression [31].
Previously, miRNA profiling has been limited to tis-
sues or cells. Evidence for circulating miRNAs is
increasing, and recent studies have detected miRNAs in
the peripheral blood of patients [32]. These peripheral
blood-isolated miRNAs could potentially be used as bio-
markers for certain diseases [33,34]. In these studies,
microvesicles/exosomes were found to serve as media-
tors of miRNA circulation. Additional studies have
Figure 4 Exosomal shuttling of miR-223 from macrophages to breast cancer cells promotes breast cancer cell invasion.( A )I L - 4 -
activated macrophages promote breast cancer cell invasion. The breast cancer cell lines SKBR3 and MDA-MB-231 were cultured alone (blank) or
co-cultured with unactivated or IL-4-activated macrophages. Approximately 24 to 48 h after co-culture, SKBR3 and MDA-MB-231 cells were
subjected to an invasion assay. Data are averages of triplicates from more than three independent experiments and are presented as the
number of invading cells per field. (B) miR-223 mimics enhanced the invasion of SKBR3 and MDA-MB-231 breast cancer cells. miR-223 was
transfected into SKBR3 and MDA-MB-231 cells. Cell invasion was then determined by a transwell invasion assay. Relative invasion activities are
presented as fold increases in the miR-223 group. The miR-NC group was normalized to 1.0. (C) Exposure to exosomes derived from
macrophages resulted in similar effects on breast cancer invasion as the actual macrophages. SKBR3 cells were incubated with exosomes derived
from unactivated or IL-4-activated macrophages and then treated with miR-NC ASO or miR-223 ASO. Cell invasion assays were performed as
shown in (A). Data are averages of triplicates from three independent experiments and are presented as the number of invading cells per field. *
p < 0.05; ** p < 0.01. (Un-Mac-exosome, exosomes originated from unactivated macrophages; IL-4-Mac-exosome, exosomes from IL-4-activated
macrophages).
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Page 9 of 13suggested that exosomes can be secreted by many cells,
including T cells [35], B cells [36], mast cells [16], den-
dritic cells [37], cancer cells [38] and macrophages [39].
Using ultracentrifugation, we isolated exosomes that
were released from macrophages. We demonstrated that
these macrophage-derived exosomes have classic struc-
tures consistent with previous reports [16]. Exosomes
have been shown to contain protein, RNA and DNA,
and much work has focused on understanding the
mechanisms of exosome-mediated cell-cell interactions
[40]. Some of these interactions involve communication
between different cell types and convey regulatory effec-
tors [41,42]; whereas, others occur among cells of the
same type [15]. Our knowledge regarding communica-
tion between macrophages and tumor cells, however, is
limited to physical contact and cytokine or chemokine
secretion [43]. More recently, human macrophages were
found to release exosomes containing migration-pro-
moting enzymes [44].
Therefore, exosomes may mediate the interactions
between macrophages and target cells by shuttling func-
tional miRNAs between them. Within the breast cancer
microenvironment, it is possible for macrophages to
communicate with cancer cells by transferring miRNAs
via exosomes. For this study, we utilized a transwell sys-
tem to mimic the tumor microenvironment; this system
allows macrophages to communicate with breast cancer
cells without physical contact. We detected a macro-
phage-dominant miRNA, miR-223, that showed an
increase in breast cancer cells following co-culture with
macrophages. To verify miRNA transport between
macrophages and breast cancer cells, we transfected
Cy3-labeled miR-223 into macrophages and tracked its
movement within the co-culture system. Once
Figure 5 miR-223 targets the Mef2c-b-catenin pathway during breast cancer cell invasion. (A) miR-223 transfection inhibited Mef2c gene
expression. HEK-293T cells were co-transfected with miR-223 and the Mef2c3 ’-UTR-directed luciferase reporter (luciferase-Mef2c; Mef2c 3’-UTR
cloned into the pMIR-REPORTER). Luciferase activities were measured as described in Figure 2. Cells transfected with miR-223 and luciferase
vector, miR-NC and luciferase-Mef2c, or miR-223 and luciferase-miR-223C (miR-223 complementary sequence cloned in the 3’-UTR of luciferase
reporter) were used as controls. Data are averages of triplicates from three independent experiments. * p < 0.05. (B) and (C) miR-223 reduced
Mef2c expression and resulted in nuclear accumulation of b-catenin. SKBR3 cells were transfected with miR-223 or miR-NC (control). The
expression of Mef2c and localisation of b-catenin in breast cancer cells were then determined by cellular fractionation followed by western blot
analysis with anti-Mef2c, b-catenin and b-actin (B). The localisation of b-catenin in SKBR3 was visualized by indirect fluorescence microscopy.
Briefly, cells were incubated with an anti-b-catenin antibody followed by an incubation with a FITC-conjugated anti-mouse secondary antibody.
PI was used to visualise the nuclei (C). (scale bar: 20 μm).
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Page 10 of 13fluorescently-labeled miRNAs were secreted from the
macrophages and captured by breast cancer cells, the
fluorescent Cy3 signal could be detected in the breast
cancer cells. As demonstrated by confocal microscopy
and flow cytometric analyses, Cy3-positive breast cancer
cells were observed, which indicates miRNA transfer.
Additionally, functional miRNA delivery was confirmed
using lin-4, a miRNA that is not expressed in mamma-
lian cells.
Next, we incubated breast cancer cells with exosomes
treated with RNase and triton X-100 to degrade the
RNA. The depletion of RNAs in exosomes significantly
decreased the invasive potential of exosomes derived
from IL-4-activated macrophages. In order to determine
t h es p e c i f i cf u n c t i o no fm i R - 2 2 3 ,w et r a n s f e c t e dm i R -
223-ASO into SKBR3 cells and then incubated these
cells with exosomes. The invasion-promoting activity of
exosomes derived from IL-4-activated macrophages on
miR-223-ASO-treated SKBR3 cells was dramatically
reduced. Moreover, when miR-223 expression in IL-4-
activated macrophages was reduced, the invasiveness of
co-cultivated breast cancer cells also decreased. Thus, it
is likely that the miR-223 delivered from macrophages,
and not the endogenous miR-223, promotes breast can-
cer cell invasion.
MDMs (monocyte-derived macrophages), prior to
activation by IL-4, were not polarized and were rela-
tively quiescent. The invasion potential of breast cancer
cells co-cultured with either unactivated macrophages
or exosomes released from unactivated macrophages
was not different from that observed for the untreated
cells. When incubated with IL-4, macrophages became
activated and polarized. IL-4, the signature cytokine of a
TH-2 type immune response, is a major activator of the
TAM phenotype in the tumor microenvironment, and
the effects of IL-4 collectively prime TAM with the abil-
ity to promote tumor growth, invasion and metastasis
[45]. When activated by IL-4, macrophages change their
cellular morphology, gene expression profile and secre-
tory pattern [46]. TAMs selectively secrete regulators or
effectors that promote tumor proliferation, invasion and
metastasis [47]. miR-223 is a miRNA associated with
tumor progress. Therefore, when activated by IL-4,
macrophages would selectively secrete more invasion-
potentiating cytokines, enzymes and miRNAs, including
miR-223, that are able to regulate the characteristics of
target cells. Our data demonstrate that there are differ-
ences between exosomes from unactivated and from IL-
4-activated macrophages in terms of size, miR-223 con-
tent, and invasion-potential.
There is a profound impact of macrophages on
breast cancer cells relative to biological function.
Therefore, the identification and verification of these
cellular interactions may provide additional strategies
to negate the tumor promoting functions of TAMs by
targeting those regulators and/or effectors which could
have significant potential in anticancer therapies. In
our studies, IL-4-activated macrophages efficiently
secrete and deliver miR-223 to breast cancer cells, and
miR-223 is responsible for macrophage-promoting
breast cancer cell invasion. Clinically, based on this
data, we could identify macrophage infiltration using
CD68 staining, and then separate tumor cells for ana-
lysis of miR-223 expression. If greater levels of macro-
phage infiltration were observed in combination with
up-regulation of miR-223 expression in tumor cells,
which would indicate a more aggressive breast cancer
phenotype according to our data, then the patient may
have a poor prognosis and alternative treatments
might be necessary. Inhibition of miR-223 in tumor
cells and/or TAMs might be helpful. Furthermore,
quantification and/or detection of miR-223 in the
serum may indicate tumor aggressiveness. Therefore, it
may be of great significance to designate miRNAs as
diagnostic or prognostic markers for breast cancer.
This will require extensive additional work to detect
miR-223 in patient serum and calculate the relation-
ship of miR-223 with prognosis, survival rate, etc.
Additionally, we explored the targets of miR-223, and
a possible mechanism through which miR-223 may pro-
mote breast cancer cell invasion. Our data do not clearly
demonstrate the invasion pathway utilized; however, our
observations indicate that the involvement of the miR-
223/Mef2c/b-catenin pathway is plausible. Additionally,
a miRNA has many targets and may function through
multiple different pathways. Currently, we are trying to
find additional targets and verify their effects using gain-
and loss-of-function assays.
The results of this study provide the first evidence
suggesting that macrophages can transfer miRNA via
exosomes to breast cancer cells. We found that the vesi-
cular miRNA is responsible for macrophage-promoting
breast cancer cell invasion, and we have provided a
rationale for therapeutically targeting miR-223 in M2
macrophages or exosomal miR-223 from M2
macrophages.
Conclusions
In conclusion, this study demonstrates that functional
miRNAs can be transported from macrophages to
breast cancer cells. Exosomes secreted from IL-4-acti-
vated macrophages shuttle miR-223 into breast cancer
cells, and miR-223 promotes breast cancer cell inva-
sion. Thus, our study provides insights into the
mechanisms of cell-cell interactions through which
macrophages regulate the invasiveness of breast cancer
cells via the exosomal-mediated delivery of oncogenic
miRNAs.
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Additional file 1: Figure S1. Macrophages infiltration in breast
tumor. Immunohistochemical staining of macrophage marker: CD68 in
invasive breast cancer samples. (A) Macrophage distribution in invasive
breast cancer of patients #1 and #2. Representative regions in #1 and #2
(200X) images were marked by rectangle and shown in (B). (B) Typical
examples of tumour cells with neighbouring macrophages. In the
marked regions, macrophages were those brown cells and adjacent
tumour cells were marked with *.
Additional file 2: Table S1. Microarray data. MicroRNA expression
profiles of breast cancer cell SKBR3, unactivated and IL-4 activated
macrophages were generated using DiscovArray miRNA arrays. All the
microarray data were listed in the table.
Additional file 3: Figure S2. Luciferase assay of miR-223 activity in
SKBR3 breast cancer cells. miR-223-targeting luciferase reporter
containing a miR-223 complementary sequence within the 3’-UTR of the
luciferase reporter gene was constructed. SKBR3 cells were transfected
with the reporter gene and cultured alone (blank) or co-cultured with IL-
4-activated or unactivated macrophages. As controls, SKBR3 cells were
co-transfected with the reporter gene or miR-NC. Relative luciferase
activities (normalised to Renilla luciferase activity) are presented. * p <
0.05.
Additional file 4: Figure S3. The fluorescent Cells co-cultured with
Cy3-proloaded macrophages were CD68 negative. SKBR3 were
cultured alone or co-cultured with IL-4 activated or unactivated
macrophages that were pre-transfected with Cy3-miR-223. Both
macrophages and SKBR3 were then stained for macrophage marker:
CD68. DAPI was used to visualize nucleus. Fluorescence signals were
determined by fluorescence microscopy. Arrows indicate Cy3 signal in
SKBR3 cells and images are shown at 1000×.
Additional file 5: Figure S4. Cy3-miR-223 was more efficiently
shuttled from IL-4 activated macrophages than that from
unactivated macrophages to breast cancer cells. SKBR3 cells were
cultured alone (blank) or co-cultured respectively with IL-4 activated or
unactivated macrophages that were pre-transfected with reagent (mock),
unlabeled miR-223 or Cy3-miR-223. Cy3-positive cells (%) were quantified
by flow cytometry. ** p < 0.01. (Un-Mac, unactivated macrophages; IL4-
Mac, IL-4-activated macrophages).
Additional file 6: Figure S5. Exosomes derived from IL-4 activated
macrophages treated by RNase plus triton X-100 had decreased
invasion potentiate. Exosomes secreted from IL-4 activated
macrophages or unactivated macrophages were treated by RNase with
or without triton X-100. SKBR3 breast cancer cells were then incubated
with those exosomes. Invasion assays were performed. Data are
presented as the number of invading cells per field (A) and
representative images of invading cells were showed in (B). ** p < 0.01.
(Un-Mac, unactivated macrophages; IL4-Mac, IL-4-activated macrophages).
Additional file 7: Figure S6. Inhibition of miR-223 expression in IL-4
activated macrophages decreased co-cultivated breast cancer cell
invasion. IL-4 activated macrophages were treated by miR-223-ASO, miR-
NC-ASO or transfection reagent only (mock) and then co-cultured with
MDA-MB-231 breast cancer cells. Breast cancer cell invasion assays were
then performed. Data are presented as the number of invading cells per
field (A) and representative images of invading cells were showed in (B).
* p < 0.05.
Additional file 8: Figure S7. SKBR3 pre-treated by miR-223-ASO
showed decreased cell invasion when co-cultured with IL-4
activated macrophages. Unactivated or IL-4 activated macrophages
respectively co-cultured with SKBR3 that pre-treated with miR-223-ASO
(miR-223-ASO treated SKBR3) or miR-NC-ASO (miR-NC-ASO treated
SKBR3). SKBR3 cell invasion was then determined by transwell invasion
assay. Relative invasion activities are presented as fold changes in the
miR-223-ASO group. The miR-NC-ASO group was normalized to 1.0. * p
< 0.05.
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